Sara Gerke (IMAGE)

University of Illinois at Urbana-Champaign, News Bureau

Sara Gerke

Caption

Phasing out animal testing in preclinical drug trials in favor of unvalidated alternate methodologies could ultimately backfire and raise safety and effectiveness concerns, says Sara Gerke, the Richard W. & Marie L. Corman Scholar at the University of Illinois Urbana-Champaign and expert in legal issues surrounding cutting-edge medical developments. 

Credit

Photo by Fred Zwicky

Usage Restrictions

No restrictions

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.